{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T23:33:28Z","timestamp":1784590408072,"version":"3.55.0"},"reference-count":20,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2007,1,1]],"date-time":"2007-01-01T00:00:00Z","timestamp":1167609600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2007,1]]},"DOI":"10.1016\/j.ijantimicag.2006.08.039","type":"journal-article","created":{"date-parts":[[2006,12,23]],"date-time":"2006-12-23T07:14:17Z","timestamp":1166858057000},"page":"62-65","source":"Crossref","is-referenced-by-count":115,"title":["Fosfomycin in the treatment of extended spectrum beta-lactamase-producing Escherichia coli-related lower urinary tract infections"],"prefix":"10.1016","volume":"29","author":[{"given":"Husnu","family":"Pullukcu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meltem","family":"Tasbakan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oguz Resat","family":"Sipahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tansu","family":"Yamazhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sohret","family":"Aydemir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sercan","family":"Ulusoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"suppl. 1","key":"10.1016\/j.ijantimicag.2006.08.039_bib1","first-page":"40","article-title":"Toplum kokenli uriner sistem infeksiyonlarindan izole edilen Escherichia coli suslarinda direnc problemi","volume":"18","author":"Arslan","year":"2005","journal-title":"Klimik Dergisi"},{"key":"10.1016\/j.ijantimicag.2006.08.039_bib2","first-page":"216","article-title":"Comparison of in vitro activity of fosfomycin and other antibacterials in Escherichia coli strains isolated from community acquired urinary tract infections","volume":"18","author":"Tasbakan","year":"2004","journal-title":"ANKEM Dergisi"},{"key":"10.1016\/j.ijantimicag.2006.08.039_bib3","first-page":"91","article-title":"Microorganisms isolated from urine specimens in the bacteriology laboratory, Uludag University Hospital between 1999\u20132002","volume":"19","author":"Yilmaz","year":"2005","journal-title":"Turk J Infect"},{"key":"10.1016\/j.ijantimicag.2006.08.039_bib4","first-page":"47","article-title":"The determination of extended spectrum beta lactamase production in various Gram negative agents responsible for nosocomial infections with two methods","volume":"17","author":"Akcam","year":"2004","journal-title":"Klimik Dergisi"},{"key":"10.1016\/j.ijantimicag.2006.08.039_bib5","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S0163-4453(03)00096-3","article-title":"Extended spectrum beta-lactamases. Implications for the clinical microbiology laboratory, therapy and infection control","volume":"47","author":"Sturenburg","year":"2003","journal-title":"J Infect"},{"key":"10.1016\/j.ijantimicag.2006.08.039_bib6","first-page":"111","article-title":"Investigation of the prevalance and susceptibility of extended spectrum beta-lactamase producing enteric bacilli in blood culture specimens","volume":"19","author":"Kizirgil","year":"2005","journal-title":"Turk J Infect"},{"key":"10.1016\/j.ijantimicag.2006.08.039_bib7","unstructured":"Pullukcu H, Aydemir S, Tasbakan M, Tunger A, Cilli F, Ulusoy S. In vitro activity of fosfomycin against extended-spectrum beta-lactamase producing Escherichia coli. Abstract e802. In: Program and Abstracts of the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy (Washington DC). American Society for Microbiology; 2005."},{"key":"10.1016\/j.ijantimicag.2006.08.039_bib8","unstructured":"National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing: 13th informational supplement M100-S13. NCCLS, Wayne, PA: USA; 2003."},{"key":"10.1016\/j.ijantimicag.2006.08.039_bib9","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1093\/jac\/dki344","article-title":"Risk factors for ciprofloxacin resistance among Escherichia coli strains isolated from community-acquired urinary tract infections in Turkey","volume":"56","author":"Arslan","year":"2005","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2006.08.039_bib10","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S0924-8579(02)00252-2","article-title":"Antibiotic prescribing and urinary tract infection","volume":"20","author":"Canbaz","year":"2002","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2006.08.039_bib11","unstructured":"Deveci O, Tayfun SS, Kaygusuz S, Kilic D, Agalar C. Uriner sistem infeksiyonu etkeni E.coli suslarinda fosfomisin duyarliliginin arastirilmasi. In: Program and Abstracts of Klimik 2005, Antalya, Turkey. [abstract p05\u201317] Klimik Dergisi 2005; 18(suppl. 1); 266."},{"key":"10.1016\/j.ijantimicag.2006.08.039_bib12","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1093\/jac\/48.5.744","article-title":"Transmissible fosfomycin resistance markers in urinary isolates and imported foodstuffs in the UK during 1994 and 1995","volume":"48","author":"Gray","year":"2001","journal-title":"J Antimicrob Chemother"},{"issue":"suppl. 2","key":"10.1016\/j.ijantimicag.2006.08.039_bib13","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/S0924-8579(03)00231-0","article-title":"Why fosfomycin trometamol as first line therapy for uncomplicated UTI?","volume":"22","author":"Schito","year":"2003","journal-title":"Int J Antimicrob Agents"},{"issue":"suppl. 2","key":"10.1016\/j.ijantimicag.2006.08.039_bib14","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0924-8579(03)00237-1","article-title":"Short term therapy for uncomplicated urinary tract infection today. Clinical outcome upholds the theories","volume":"22","author":"Lobel","year":"2003","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2006.08.039_bib15","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0924-8579(98)00021-1","article-title":"A comparison between single-dose FT and a 5-day course of trimethoprim in the treatment of uncomplicated lower urinary tract infection in women","volume":"10","author":"Minassian","year":"1998","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2006.08.039_bib16","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1128\/AAC.38.11.2612","article-title":"Single-dose fosfomycin trometamol versus 5-day cephalexin regimen for treatment of uncomplicated lower urinary tract infections in women","volume":"38","author":"Elhanan","year":"1994","journal-title":"Antimicrob Agents Chemother"},{"issue":"suppl. 2","key":"10.1016\/j.ijantimicag.2006.08.039_bib17","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1007\/BF01643433","article-title":"Fosfomycin trometamol in a single-dose versus norfloxacin for 7 days in the treatment of uncomplicated urinary infections in general practice","volume":"18","author":"Boerema","year":"1990","journal-title":"Infection"},{"key":"10.1016\/j.ijantimicag.2006.08.039_bib18","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/BF01871127","article-title":"Fosfomycin trometamol in a single-dose versus 7 days nitrofurantoin in the treatment of acute uncomplicated urinary tract infections in women","volume":"15","author":"Van Pienbroek","year":"1993","journal-title":"Pharm World Sci"},{"key":"10.1016\/j.ijantimicag.2006.08.039_bib19","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1093\/clinids\/21.1.86","article-title":"A multicenter comparative study of meropenem and imipenem\/cilastatin in the treatment of complicated urinary tract infections in hospitalized patients","volume":"21","author":"Cox","year":"1995","journal-title":"Clin Infect Dis"},{"issue":"suppl. 1","key":"10.1016\/j.ijantimicag.2006.08.039_bib20","doi-asserted-by":"crossref","first-page":"S216","DOI":"10.1093\/clind\/15.Supplement_1.S216","article-title":"Evaluation of new anti-infective drugs for the treatment of urinary tract infection. Infectious Diseases Society of America and the Food and Drug Administration","volume":"15","author":"Rubin","year":"1992","journal-title":"Clin Infect Dis"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092485790600392X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092485790600392X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,1,10]],"date-time":"2019-01-10T10:27:12Z","timestamp":1547116032000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S092485790600392X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,1]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2007,1]]}},"alternative-id":["S092485790600392X"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2006.08.039","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.1147211.604355","asserted-by":"object"}]},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2007,1]]}}}